Sectoral AM launches new biotech fund

Swiss investment firm Sectoral Asset Management has launched a new biotech strategy, the Variopartner SICAV – Sectoral Biotech Opportunities Fund with initial assets of over $50m (€44.1m).

The fund invests in innovative biotech companies and focuses on small and mid caps. Its portfolio consists of 30 high conviction positions and the stock selection applies a bottom-up approach.

Sectoral emphasised that medical innovation is developing fast, particularly in the areas of cancer and gene therapy.

The manager recalled 2015 has been a record year in terms of new product launches with 45 new drugs having been approved by the FDA.

Sectoral AM sets a fund size target comprised between $300m (€264.4m) and $500m (€440.7m).

Part of the starting fund assets were raised by Bonhôte Fund Solutions, an investment platform including Bordier & Cie as well as other institutional partners.

Michael Sjöström, CIO and co-founder of Sectoral, said : “This new fund is clearly differentiated from large traditional biotech funds and ETFs”.

Mina Marmor, portfolio manager of the Sectoral Biotech Opportunities Fund, added: “After the recent correction, biotech valuations have retreated to levels not seen in five years.

“Given the strong pipeline of the industry, a favourable regulatory framework for drugs targeting rare or severe diseases and the growing demand for innovative drugs, the industry is poised to deliver attractive returns to investors.”

Close Window
View the Magazine

You need to fill all required fields!